Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery

Annual Review of Physiology

Volumn 74, Issue , 2012, Pages 153-175

  Colgan, Sean P ^a   Eltzschig, Holger K ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Colitis; Endothelium; Epithelium; Inflammation; Ischemia; Metabolism; Mucosa; Murine model; Neutrophil; Nucleoside; Nucleotidase; Nucleotide

Indexed keywords

ADENOSINE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; HYDROXYL RADICAL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; REACTIVE OXYGEN METABOLITE;

ADAPTIVE IMMUNITY; ARTICLE; CELL CULTURE; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; ENTERITIS; GASTROINTESTINAL TRACT; GLUCOSE INTAKE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HYPOXIA; INFLAMMATION; INNATE IMMUNITY; INTESTINE INJURY; MITOCHONDRION; MYELOID DENDRITIC CELL; NEUTROPHIL; NONHUMAN; NUCLEIC ACID METABOLISM; NUCLEOTIDE METABOLISM; PATHOGENESIS; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THYMOCYTE;

5'-NUCLEOTIDASE; ADENOSINE; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; ANOXIA; EXTRACELLULAR SPACE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNITY, MUCOSAL; INFLAMMATION; INTESTINAL DISEASES; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MICE; NUCLEOTIDES; PROCOLLAGEN-PROLINE DIOXYGENASE; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION;

EID: 84857076647     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-020911-153230     Document Type: Article

References (147)

1. Laukoetter MG, Bruewer M, Nusrat A. 2006. Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr. Opin. Gastroenterol. 22:85-89 (Pubitemid 44090070)
2. Turner JR. 2009. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9:799-809
3. Furuta GT, Turner JR, Taylor CT, Hershberg RM, Comerford KM, et al. 2001. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J. Ex. Med. 193:1027-34 (Pubitemid 32436196)
4. Taylor CT, Colgan SP. 2008. Hypoxia and gastrointestinal disease. J. Mol. Med. 85:1295-300 (Pubitemid 50004090)
5. Colgan SP, Taylor CT. 2010. Hypoxia: an alarm signal during intestinal inflammation. Nat. Rev. Gastroenterol. Hepatol. 7:281-87
6. Kominsky DJ, Campbell EL, Colgan SP. 2010. Metabolic shifts in immunity and inflammation. J. Immunol. 184:4062-68
7. Pollard TD, Borisy GG. 2003. Cellular motility driven by assembly and disassembly of actin filaments. Cell 112:453-65 (Pubitemid 36263079)
8. Borregaard N, Herlin T. 1982. Energy metabolism of human neutrophils during phagocytosis. J. Clin. Investig. 70:550-57 (Pubitemid 12054579)
9. El-Benna J, Dang PM, Gougerot-Pocidalo MA. 2008. Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin. Immunopathol. 30:279-89
10. Gabig TG, Bearman SI, Babior BM. 1979. Effects of oxygen tension and pH on the respiratory burst of human neutrophils. Blood 53:1133-39 (Pubitemid 10238919)
11. Greiner EF, Guppy M, Brand K. 1994. Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J. Biol. Chem. 269:31484-90 (Pubitemid 24379505)
12. Plas DR, Rathmell JC, Thompson CB. 2002. Homeostatic control of lymphocyte survival: potential origins and implications. Nat. Immunol. 3:515-21 (Pubitemid 34662302)
13. Fox CJ, Hammerman PS, Thompson CB. 2005. Fuel feeds function: energy metabolism and the T-cell response. Nat. Rev. Immunol. 5:844-52 (Pubitemid 41581666)
14. Hatoum OA, Heidemann J, Binion DG. 2006. The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann. N. Y. Acad. Sci. 1072:78-97 (Pubitemid 44448445)
15. Danese S, Dejana E, Fiocchi C. 2007. Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J. Immunol. 178:6017-22 (Pubitemid 46717378)
16. Karhausen JO, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. 2004. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J. Clin. Investig. 114:1098-106 (Pubitemid 39578699)
17. Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, et al. 2000. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res. 60:2018-24 (Pubitemid 30207665)
18. Takasawa M, Moustafa RR, Baron JC. 2008. Applications of nitroimidazole in vivo hypoxia imaging in ischemic stroke. Stroke 39:1629-37
19. Kizaka-Kondoh S, Konse-Nagasawa H. 2009. Significance of nitroimidazole compounds and hypoxiainducible factor-1 for imaging tumor hypoxia. Cancer Sci. 100:1366-73
20. Overgaard J. 2007. Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol. 25:4066-74 (Pubitemid 47492951)
21. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. 2009. HIF-2α, but not HIF-1α, promotes iron absorption in mice. J. Clin. Investig. 119:1159-66
22. Ratcliffe PJ. 2007. HIF-1 and HIF-2: working alone or together in hypoxia? J. Clin. Investig. 117:862-65 (Pubitemid 46556739)
23. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, et al. 2002. Ecto-5prime;-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 (HIF-1) mediates permeability changes in intestinal epithelia. J. Clin. Investig. 110:993-1002
24. Cummins EP, Seeballuck F, Keely SJ, Mangan NE, Callanan JJ, et al. 2008. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 134:156-65
25. Han IO, Kim HS, Kim HC, Joe EH, Kim WK. 2003. Synergistic expression of inducible nitric oxide synthase by phorbol ester and interferon-γ is mediated through NF-κB and ERK in microglial cells. J. Neurosci. Res. 73:659-69
26. Morote-Garcia JC, Rosenberger P, Nivillac NM, Coe IR, Eltzschig HK. 2009. Hypoxia-inducible factordependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology 136:607-18
27. Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, Colgan SP. 2008. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 134:145-55 (Pubitemid 350309309)
28. Shah YM, Ito S, Morimura K, Chen C, Yim SH, et al. 2008. Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology 134:2036-48
29. Giatromanolaki A, Sivridis E, Maltezos E, Papazoglou D, Simopoulos C, et al. 2003. Hypoxia inducible factor 1αand 2αoverexpression in inflammatory bowel disease. J. Clin. Pathol. 56:209-13 (Pubitemid 36308037)
30. Mariani F, Sena P, Marzona L, Riccio M, Fano R, et al. 2009. Cyclooxygenase-2 and Hypoxia-Inducible Factor-1α protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis. Cancer Lett. 279:221-29
31. Matthijsen RA, Derikx JP, Kuipers D, vanDam RM, Dejong CH, Buurman WA. 2009. Enterocyte shedding and epithelial lining repair following ischemia of the human small intestine attenuate inflammation. PLoS ONE 4:e7045
32. Louis NA, Hamilton KE, Canny G, Shekels LL, Ho SB, Colgan SP. 2006. Selective induction of mucin-3 by hypoxia in intestinal epithelia. J. Cell Biochem. 99:1616-27 (Pubitemid 44845721)
33. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. 2002. Hypoxiainducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62:3387-94 (Pubitemid 34651384)
34. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, et al. 2003. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J. Ex. Med. 198:783-96 (Pubitemid 37087777)
35. Makino Y, Nakamura H, Ikeda E, Ohnuma K, Yamauchi K, et al. 2003. Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J. Immunol. 171:6534-40 (Pubitemid 37532083)
36. Sitkovsky M, Lukashev D. 2005. Regulation of immune cells by local-tissue oxygen tension: HIF1αand adenosine receptors. Nat. Rev. Immunol. 5:712-21 (Pubitemid 43086172)
37. Nizet V, Johnson RS. 2009. Interdependence of hypoxic and innate immune responses. Nat. Rev. Immunol. 9:609-17
38. Kong T, Eltzschig HK, Karhausen J, Colgan SP, Shelley CS. 2004. Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of β2 integrin gene expression. Proc. Natl. Acad. Sci. USA 101:10440-45 (Pubitemid 38924944)
39. Kuhl AA, Kakirman H, Janotta M, Dreher S, Cremer P, et al. 2007. Aggravation of different types of experimental colitis by depletion or adhesion blockade of neutrophils. Gastroenterology 133:1882-92 (Pubitemid 350180801)
40. Kaelin WG Jr, Ratcliffe PJ. 2008. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30:393-402 (Pubitemid 351681994)
41. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, et al. 2006. Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity. Proc. Natl. Acad. Sci. USA 103:18154-59 (Pubitemid 44871628)
42. Aragones J, Schneider M, Van Geyte K, Fraisl P, Dresselaers T, et al. 2008. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat. Genet. 40:170-80 (Pubitemid 351171394)
43. Schneider M, Van Geyte K, Fraisl P, Kiss J, Aragones J, et al. 2009. Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. Gastroenterology 138:1143-54
44. Tambuwala MM, Cummins EP, Lenihan CR, Kiss J, Stauch M, et al. 2010. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 139:2093-101
45. Mazzone M, Dettori D, Leite deOliveira R, Loges S, Schmidt T, et al. 2009. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136:839-51
46. Ozolins TR, Fisher TS, Nadeau DM, Stock JL, Klein AS, et al. 2009. Defects in embryonic development of EGLN1/PHD2 knockdown transgenic mice are associated with induction of Igfbp in the placenta. Biochem. Biophys. Res. Commun. 390:372-76
47. Bishop T, Gallagher D, Pascual A, Lygate CA, de Bono JP, et al. 2008. Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice. Mol. Cell. Biol. 28:3386-400 (Pubitemid 351657101)
48. Taylor CT. 2008. Interdependent roles for hypoxia inducible factor and nuclear factor-κB in hypoxic inflammation. J. Physiol. 586:4055-59
49. Rosenberger P, Khoury J, Kong T, Weissmuller T, Robinson AM, Colgan SP. 2007. Identification of vasodilator-stimulated phosphoprotein (VASP) as an HIF-regulated tissue permeability factor during hypoxia. FASEB J. 21:2613-21 (Pubitemid 47230689)
50. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, et al. 1995. Signal-induced site-specific phosphorylation targets IκBαto the ubiquitin-proteasome pathway. Genes Dev. 9:1586-97
51. Luo JL, Kamata H, Karin M. 2005. IKK/NF-κB signaling: balancing life and death-a new approach to cancer therapy. J. Clin. Investig. 115:2625-32 (Pubitemid 41434385)
52. Chen ZJ. 2005. Ubiquitin signalling in the NF-κB pathway. Nat. Cell Biol. 7:758-65
53. Cockman ME, Lancaster DE, Stolze IP, Hewitson KS, McDonough MA, et al. 2006. Posttranslational hydroxylation of ankyrin repeats in IκB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc. Natl. Acad. Sci. USA 103:14767-72 (Pubitemid 44527803)
54. Zaph C, Troy AE, Taylor BC, Berman-Booty LD, Guild KJ, et al. 2007. Epithelial-cell-intrinsic IKK-β expression regulates intestinal immune homeostasis. Nature 446:552-56 (Pubitemid 46514719)
55. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, et al. 2008. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 453:807-11 (Pubitemid 351793778)
56. Coleman ML, McDonough MA, Hewitson KS, Coles C, Mecinovic J, et al. 2007. Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J. Biol. Chem. 282:24027-38 (Pubitemid 47328043)
57. Koditz J, Nesper J, Wottawa M, Stiehl DP, Camenisch G, et al. 2007. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 110:3610-17 (Pubitemid 350159628)
58. Mole DR, Schlemminger I, McNeill LA, Hewitson KS, Pugh CW, et al. 2003. 2-Oxoglutarate analogue inhibitors of HIF prolyl hydroxylase. Bioorg. Med. Chem. Lett. 13:2677-80 (Pubitemid 36851548)
59. Masson N, Ratcliffe PJ. 2003. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O2 levels. J. Cell Sci. 116:3041-49 (Pubitemid 37038953)
60. Schofield CJ, Ratcliffe PJ. 2004. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 5:343-54 (Pubitemid 38579472)
61. Bruick RK. 2003. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes. Dev. 17:2614-23 (Pubitemid 37363065)
62. Jelkmann W. 2007. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol. 435:179-97
63. Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, et al. 2010. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J. Am. Soc. Nephrol. 21:2151-56
64. Drury AN, Szent-Gyorgyi A. 1929. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol. 68:213-37
65. Belhassen B, Pelleg A. 1984. Electrophysiologic effects of adenosine triphosphate and adenosine on the mammalian heart: clinical and experimental aspects. J. Am. Coll. Cardiol. 4:414-24 (Pubitemid 14053572)
66. Delacretaz E. 2006. Clinical practice. Supraventricular tachycardia. N. Engl. J. Med. 354:1039-51
67. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, et al. 2003. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Supraventricular Arrhythmias). Circulation 108:1871-909 (Pubitemid 37303907)
68. Eltzschig HK. 2009. Adenosine: an old drug newly discovered. Anesthesiology 111:904-15
69. Koeppen M, Eckle T, Eltzschig HK. 2009. Selective deletion of the A1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS ONE 4:e6784
70. Matherne GP, Linden J, Byford AM, Gauthier NS, Headrick JP. 1997. Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc. Natl. Acad. Sci. USA 94:6541-46 (Pubitemid 27270721)
71. Yang JN, Chen JF, Fredholm BB. 2009. Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. Am. J. Physiol. Heart Circ. Physiol. 296:1141-49
72. Picano E, Trivieri MG. 1999. Pharmacologic stress echocardiography in the assessment of coronary artery disease. Curr. Opin. Cardiol. 14:464-70
73. Hart ML, Kohler D, Eckle T, Kloor D, Stahl GL, Eltzschig HK. 2008. Direct treatment of mouse or human blood with soluble 5prime;-nucleotidase inhibits platelet aggregation. Arterioscler. Thromb. Vasc. Biol. 28:1477-83
74. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, et al. 2008. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359:1238-51
75. Fanta CH. 2009. Asthma. N. Engl. J. Med. 360:1002-14
76. Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K. 2005. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin. Thromb. Hemost. 31:217-33 (Pubitemid 40605196)
77. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. 2006. Physiological roles of 5prime;-ectonucleotidase (CD73). Purinergic Signal. 2:351-60
78. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, et al. 2002. Ecto-5prime;-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Investig. 110:993-1002
79. Bauerle JD, Grenz A, Kim JH, Lee HT, Eltzschig HK. 2011. Adenosine generation and signaling during acute kidney injury. J. Am. Soc. Nephrol. 22:14-20
80. Eckle T, Koeppen M, Eltzschig HK. 2009. Role of extracellular adenosine in acute lung injury. Physiology 24:298-306
81. Loffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, Eltzschig HK. 2007. Physiological roles of vascular nucleoside transporters. Arterioscler. Thromb. Vasc. Biol. 27:1004-13 (Pubitemid 46641985)
82. Eltzschig HK, Faigle M, Knapp S, Karhausen J, Ibla J, et al. 2006. Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26. Blood 108:1602-10 (Pubitemid 44316128)
83. Morote-Garcia JC, Rosenberger P, Kuhlicke J, Eltzschig HK. 2008. HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood 111:5571-80
84. Aherne CM, Kewley EM, Eltzschig HK. 2010. The resurgence of A2B adenosine receptor signaling. Biochim. Biophys. Acta 1808:1329-39
85. Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, et al. 2010. Pannexin 1 channels mediate "find-me" signal release and membrane permeability during apoptosis. Nature 467:863-67
86. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, et al. 2009. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461:282-86
87. Eltzschig HK, Eckle T, Mager A, Kuper N, Karcher C, et al. 2006. ATPrelease from activated neutrophils occurs via connexin 43 andmodulates adenosine-dependent endothelial cell function. Circ. Res. 99:1100-8 (Pubitemid 44729934)
88. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, et al. 2003. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J. Exp. Med. 198:783-96 (Pubitemid 37087777)
89. Novak I. 2003. ATP as a signaling molecule: the exocrine focus. News Physiol. Sci. 18:12-17 (Pubitemid 36299377)
90. Goodenough DA, Paul DL. 2003. Beyond the gap: functions of unpaired connexon channels. Nat. Rev. Mol. Cell Biol. 4:285-94 (Pubitemid 36383955)
91. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, et al. 2006. ATPrelease guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314:1792-95 (Pubitemid 44969094)
92. Linden J. 2006. Purinergic chemotaxis. Science 314:1689-90 (Pubitemid 44969062)
93. Gordon JL. 1986. Extracellular ATP: effects, sources and fate. Biochem. J. 233:309-19 (Pubitemid 16169477)
94. Weissmuller T, Campbell EL, Rosenberger P, Scully M, Beck PL, et al. 2008. PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases. J. Clin. Investig. 118:3682-92
95. Madara JL, Patapoff TW, Gillece-Castro B, Colgan SP, Parkos CA, et al. 1993. 5prime;-Adenosine monophosphate is the neutrophil-derived paracrine factor that elicits chloride secretion from T84 intestinal epithelial cell monolayers. J. Clin. Investig. 91:2320-25 (Pubitemid 23141512)
96. Zimmermann H. 2000. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch. Pharmacol. 362:299-309
97. Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, et al. 2002. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J. Clin. Investig. 109:1031-40 (Pubitemid 34408578)
98. Marcus AJ, Broekman MJ, Drosopoulos JHF, Islam N, Alyonycheva TN, et al. 1997. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J. Clin. Investig. 99:1351-60 (Pubitemid 27142773)
99. Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, et al. 2007. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 116:1784-94 (Pubitemid 350287103)
100. Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS, et al. 1999. Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat. Med. 5:1010-17 (Pubitemid 29439571)
101. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP. 2009. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 113:224-32
102. Maliszewski CR, Delespesse GJ, Schoenborn MA, Armitage RJ, Fanslow WC, et al. 1994. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J. Immunol. 153:3574-83 (Pubitemid 24313861)
103. Friedman DJ, Künzli BM, A-Rahim YI, Sevigny J, Berberat PO, et al. 2009. CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 106:16788-93
104. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, et al. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204:1257-65 (Pubitemid 46919862)
105. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, et al. 2004. Crucial role for ecto-5prime;- nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med. 200:1395-405 (Pubitemid 39657287)
106. Louis NA, Robinson AM, MacManus CF, Karhausen J, Scully M, Colgan SP. 2008. Control of IFN-αA by CD73: implications for mucosal inflammation. J. Immunol. 180:4246-55
107. Hart ML, Henn M, Kohler D, Kloor D, Mittelbronn M, et al. 2008. Role of extracellular nucleotide phosphohydrolysis in intestinal ischemia-reperfusion injury. FASEB J. 22:2784-97
108. Hart ML, Grenz A, Gorzolla IC, Schittenhelm J, Dalton JH, Eltzschig HK. 2011. Hypoxiainducible factor-1α-dependent protection from intestinal ischemia/reperfusion injury involves ecto- 5prime;-nucleotidase (CD73) and the A2B adenosine receptor. J. Immunol. 186:4367-74
109. St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, et al. 2011. NT5E mutations and arterial calcifications. N. Engl. J. Med. 364:432-42
110. Terkeltaub R. 2006. Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/ phosphodiesterase family focusing on NPP1 in calcification. Purinergic Signal. 2:371-77
111. Eltzschig HK, Robson SC. 2011. NT5E mutations and arterial calcifications. N. Engl. J. Med. 364:1577-78
112. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, et al. 2011. Structure of an agonist-bound human A2A adenosine receptor. Science 332:322-27
113. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP. 2006. HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J. 20:2242-50 (Pubitemid 44953854)
114. Ahmad A, Ahmad S, Glover LE, Miller S, Shannon JM, et al. 2009. Adenosine A2A receptor is a unique angiogenic target of HIF-2αin pulmonary endothelial cells. Proc. Natl. Acad. Sci. USA 106:10684-89
115. Fredholm BB. 2007. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 14:1315-23 (Pubitemid 46965261)
116. Hart ML, Jacobi B, Schittenhelm J, Henn M, EltzschigHK. 2009. Cutting edge: A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J. Immunol. 182:3965-68
117. Frick JS, MacManus CF, Scully M, Glover LE, Eltzschig HK, Colgan SP. 2009. Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. J. Immunol. 182:4957-64
118. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, et al. 2004. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 104:3986-92 (Pubitemid 39620148)
119. Grenz A, Homann D, Eltzschig HK. 2011. Extracellular adenosine: a "safety signal" that dampens hypoxia-induced inflammation during ischemia. Antioxid. Redox Signal. 15(8):2221-34
120. Ohta A, Sitkovsky M. 2001. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916-20 (Pubitemid 34024743)
121. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, et al. 2004. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22:657-82 (Pubitemid 38680437)
122. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. 2006. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J. Exp. Med. 203:2639-48 (Pubitemid 44833340)
123. Corset V, Nguyen-Ba-Charvet KT, Forcet C, Moyse E, Chedotal A, Mehlen P. 2000. Netrin-1- mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor. Nature 407:747-50
124. Ly NP, Komatsuzaki K, Fraser IP, Tseng AA, Prodhan P, et al. 2005. Netrin-1 inhibits leukocyte migration in vitro and in vivo. Proc. Natl. Acad. Sci. USA 102:14729-34 (Pubitemid 41457124)
125. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, et al. 2009. Hypoxia-inducible factordependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat. Immunol. 10:195-202
126. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, et al. 2005. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J. Exp. Med. 202:1493-505 (Pubitemid 41746596)
127. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. 2004. The equilibrative nucleoside transporter family, SLC29. Pflüg. Arch. 447:735-43 (Pubitemid 38241459)
128. Griffiths M, Beaumont N, Yao SY, Sundaram M, Boumah CE, et al. 1997. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat. Med. 3:89-93 (Pubitemid 27019148)
129. Coe IR, Griffiths M, Young JD, Baldwin SA, Cass CE. 1997. Assignment of the human equilibrative nucleoside transporter (hENT1) to 6p21. 1-p21. 2. Genomics 45:459-60 (Pubitemid 27467647)
130. Casanello P, Torres A, Sanhueza F, Gonzalez M, Farias M, et al. 2005. Equilibrative nucleoside transporter 1 expression is downregulated by hypoxia in human umbilical vein endothelium. Circ. Res. 97:16-24 (Pubitemid 40982318)
131. Chaudary N, Naydenova Z, Shuralyova I, Coe IR. 2004. Hypoxia regulates the adenosine transporter, mENT1, in the murine cardiomyocyte cell line, HL-1. Cardiovasc. Res. 61:780-88 (Pubitemid 38249477)
132. Rose JB, Naydenova Z, Bang A, Eguchi M, Sweeney G, et al. 2009. Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 298:771-77
133. Hart ML, Much C, Kohler D, Schittenhelm J, Gorzolla IC, et al. 2008. Use of a hanging-weight system for liver ischemic preconditioning in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 294:1431-40
134. Eckle T, Grenz A, Kohler D, Redel A, Falk M, et al. 2006. Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. Am. J. Physiol. Heart Circ. Physiol. 291:2533-40
135. Decking UKM, Schlieper G, Kroll K, Schrader J. 1997. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ. Res. 81:154-64 (Pubitemid 27342482)
136. Peart JN, Gross GJ. 2005. Cardioprotection following adenosine kinase inhibition in rat hearts. Basic Res. Cardiol. 100:328-36 (Pubitemid 40974083)
137. Ely SW, Matherne GP, Coleman SD, Berne RM. 1992. Inhibition of adenosine metabolism increases myocardial interstitial adenosine concentrations and coronary flow. J. Mol. Cell Cardiol. 24:1321-32 (Pubitemid 23016054)
138. PakMA, Haas HL, Decking UK, Schrader J. 1994. Inhibition of adenosine kinase increases endogenous adenosine and depresses neuronal activity in hippocampal slices. Neuropharmacology 33:1049-53
139. Khoury J, Ibla JC, Neish AS, Colgan SP. 2007. Antiinflammatory adaptation to hypoxia through adenosine-mediated cullin-1 deneddylation. J. Clin. Investig. 117:703-11 (Pubitemid 46348528)
140. Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, et al. 2000. Prokaryotic regulation of epithelial responses by inhibition of IκB-αubiquitination. Science 289:1560-63
141. Cope GA, Deshaies RJ. 2003. COP9 signalosome: a multifunctional regulator of SCF and other cullinbased ubiquitin ligases. Cell 114:663-71 (Pubitemid 37186763)
142. Cardozo T, Pagano M. 2004. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 5:739-51 (Pubitemid 39208183)
143. Parry G, Estelle M. 2004. Regulation of cullin-based ubiquitin ligases by theNedd8/RUB ubiquitin-like proteins. Semin. Cell Dev. Biol. 15:221-29 (Pubitemid 38251651)
144. Mendoza HM, Shen LN, Botting C, Lewis A, Chen J, et al. 2003. NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins. J. Biol. Chem. 278:25637-43 (Pubitemid 36835317)
145. Wu K, Yamoah K, Dolios G, Gan-Erdene T, Tan P, et al. 2003. DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1. J. Biol. Chem. 278:28882-91 (Pubitemid 36935799)
146. Castillo CA, Leon D, Ruiz MA, Albasanz JL, Martin M. 2008. Modulation of adenosineA1 andA2A receptors in C6 glioma cells during hypoxia: involvement of endogenous adenosine. J. Neurochem. 105:2315-29 (Pubitemid 351782258)
147. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, et al. 2005. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J. Exp. Med. 202:1493-505 (Pubitemid 41746596)